Context.—Controversies and uncertainty persist in prostate cancer grading. Objective.—To
update grading recommendations. Data Sources.—Critical review of the literature along with …

Over the past years, several studies have demonstrated that defects in DNA damage
response and repair (DDR) genes are present in a significant proportion of patients with …

Purpose: The summary presented herein represents Part I of the three-part series dedicated
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …

PURPOSE Germline testing (GT) is a central feature of prostate cancer (PCA) treatment,
management, and hereditary cancer assessment. Critical needs include optimized …

PURPOSE This guideline provides recommendations for available tissue-based prostate
cancer biomarkers geared toward patient selection for active surveillance, identification of …

Background Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate
cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate …

Background Deleterious ATM alterations are found in metastatic prostate cancer (PC); PARP
inhibition has antitumour activity against this subset, but only some ATM loss PCs respond …

Prostate cancer is the most frequent nonskin cancer and second most common cause of
cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with …

Genetic testing for prostate cancer is rapidly growing and is increasingly being driven by
precision medicine. Rates of germline pathogenic variants have been reported in up to 15 …

Objective Evidence shows that gene mutation is a significant proportion of genetic factors
associated with prostate cancer. The DNA damage response (DDR) is a signal cascade …